1.bcr_3/abl_2 ANTISENSE OLIGODEOXYNUCLEOTIDE INDUCES APOPTOSIS IN CHRONIC MYELOID LEUKEMIA
Zhenchuan SHANG ; Bingzhong SUN ; Xiaoping XIE
China Oncology 1998;0(04):-
PURPOSE To investigate the effects of bcr3/abl2 anisense oligodeoxynucleotide (ASO) on chronic myeloid leukemia (CML). METHODS The effects of bcr3/abl2 ASO in 15 CML patients were evaluated by morphological observation, flow cytometer (FCM) techniques and DNA fragment measurement. RESULTS bcr3/abl2 ASO can induce apoptosis in CML. CONCLUSION Antisense techniques may provide a new way to cure CML.
2.Hospital Infection after Hemopoietic Stem Cell Transplantation:Clinical Analysis of 21 Cases
Ling ZHANG ; Zhenchuan SHANG ; Chunrong SU ; Haoping SUN
Chinese Journal of Nosocomiology 2005;0(11):-
OBJECTIVE To study the rate and the risk factors of hospital infection after hemopoietic stem cell transplantation and improve treatment strategy.METHODS The clinical data of 21 cases of hemopoietic stem cell transplantation were analyzed respectively in our hospital.RESULTS Hospital infection was found in 15 cases,the infection rate was 71.4%.Fifteen kinds of bacteria and 4 kinds of fungi were observed.The risk factors were aggressive operation,the abuse of glucocorticoid and antibiotics.CONCLUSIONS The patients have a high rate of hospital infection after hemopoietic stem cell transplantation and a poor prognosis because of hospital infection.To decrease the rate of hospital infection after hemopoietic stem cell transplantation,the whole environmental protection should be carried out except decreased aggressive operation and the correct use of glucocorticoid and antibiotics.
3.The effect of multi-unit ribozymes on the growth inhibition and apoptosis induction of CML K562 cells.
Qi FENG ; Bingzhong SUN ; Kai SUN ; Zhenchuan SHANG ; Sha WANG ; Wei WANG ; Yongtong ZHAO ; Zhen YAN ; Wei HAN ; Yingqi ZHANG
Chinese Journal of Oncology 2002;24(5):435-439
OBJECTIVETo investigate the possibility of multi-unit ribozymes to purge bone marrow of chronic myelocytic leukemia (CML), its in vitro cleavage ability and the reversal effect on CML cell's malignant phenotype.
METHODSAs bcr-abl fusion gene plays an important role in CML pathology, three single-unit ribozymes were designed and synthesized in 44 base pairs near the fusion point, two enzyme cleavage sites on bcr gene and one on abl gene. Multi-unit ribozymes' in vitro transcription and retroviral vector through gene recombination were constructed. Then, its in vitro cleavage ability was tested and the retroviral vector was transfected into K562 cell. Through MTT assay, the incorporation rate of (3)H-TdR, RT-PCR, Southern and Northern blot hybridization, flow cytometry, transmission and scanning electron microscopy were used to study the effect of multi-unit ribozymes on CML cell proliferation, cell structure, cell cycle and the induction of apoptosis.
RESULTSMulti-unit ribozymes had in vitro cleavage efficiency of 70.8%. After the transfection of multi-unit ribozymes retroviral vector into K562 cell, cell proliferation and DNA synthesis were greatly reduced with an inhibition rate of about 50% after 96 hours of transfection. Multi-unit ribozymes could cleave K562 cell's RNA with a reduction rate about one 1 000 th of the original. By flow cytometry (FCM), 18.4% cells underwent apoptosis after 72 hours transfection with most of the cells blocked in the G phase. Here, the ratio in S phase was lowered by 41.9%. Under transmission and scanning electron microscope, compaction of nuclear chromation and apoptosis bodies were observed in the transfected cells.
CONCLUSIONMulti-unit ribozymes possess high cleavage ability in vitro. The ribozymes, whose retroviral vector being transfected into CML cell, are able to express a lasting ability to cleave the fusion gene, induce apoptosis, reduce cell proliferation, revert the malignant phenotype. It is possible to make use of multi-unit ribozymes to purge CML bone marrow. Therefore, multi-unit ribozymes may very well be valuable in the gene therapy of CML.
Apoptosis ; Cell Division ; drug effects ; Fusion Proteins, bcr-abl ; genetics ; metabolism ; Humans ; K562 Cells ; RNA, Catalytic ; metabolism ; pharmacology